TECHNETIUM TC 99M MERTIATIDE KIT Drug Patent Profile

« Back to Dashboard

Which patents cover Technetium Tc 99m Mertiatide Kit, and what generic alternatives are available?

Technetium Tc 99m Mertiatide Kit is a drug marketed by Jubilant Draximage and is included in one NDA.

The generic ingredient in TECHNETIUM TC 99M MERTIATIDE KIT is technetium tc-99m mertiatide kit. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m mertiatide kit profile page.

Summary for TECHNETIUM TC 99M MERTIATIDE KIT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	TECHNETIUM TC 99M MERTIATIDE KIT at DailyMed

US Patents and Regulatory Information for TECHNETIUM TC 99M MERTIATIDE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Draximage	TECHNETIUM TC 99M MERTIATIDE KIT	technetium tc-99m mertiatide kit	POWDER;INTRAVENOUS	216820-001	Jan 30, 2023		RX	Yes	Yes

Technetium Tc 99m Mertiatide Kit Market Dynamics and Financial Trajectory

Last updated: October 4, 2026

Technetium Tc 99m mertiatide kit, commonly known as Tc-99m MAG3 or mercaptoacetyltriglycine, is a mature renal-imaging radiopharmaceutical used for dynamic renal scintigraphy, differential renal function, urinary obstruction assessment, and transplant evaluation. Its commercial outlook is stable rather than high growth. Demand is supported by an aging population, chronic kidney disease, pediatric urology, and continued nuclear-medicine infrastructure. Revenue is constrained by generic-style competition, hospital purchasing pressure, alternative imaging modalities, radiopharmaceutical supply interruptions, and the absence of meaningful exclusivity.

Standalone product revenue is generally not disclosed by manufacturers. Financial analysis therefore relies on procedure demand, kit utilization, nuclear-pharmacy distribution, reimbursement, and supplier performance rather than reported brand sales.

What is Technetium Tc 99m mertiatide kit used for?

Technetium Tc 99m mertiatide kit is a diagnostic kit for preparing technetium Tc 99m mertiatide injection. The kit contains the nonradioactive ligand and excipients. A nuclear pharmacy or authorized radiopharmacy adds sodium pertechnetate Tc 99m immediately before administration.

The principal clinical uses are:

• Dynamic renal imaging and renography
• Measurement of relative renal function
• Evaluation of suspected urinary tract obstruction
• Assessment of renal perfusion and drainage
• Evaluation of renal transplants
• Pediatric urologic imaging, often with diuretic challenge

The product is favored for renal imaging because Tc-99m mertiatide has high renal extraction and rapid urinary clearance. Its performance supports functional imaging where anatomic tests alone may not establish drainage or split renal function.

The FDA labeling identifies the product as a diagnostic radiopharmaceutical kit rather than a therapeutic medicine. The radioactive dose is prepared shortly before use, which makes the product dependent on local radiopharmacy operations and the availability of Tc-99m generators or centralized isotope distribution systems (U.S. Food and Drug Administration [FDA], n.d.-a).

How large is the Technetium Tc 99m mertiatide market?

No authoritative public source provides a consolidated global revenue figure for Tc-99m mertiatide kits. Manufacturers generally report broader radiopharmaceutical or imaging businesses rather than MAG3 sales separately.

The addressable market is best defined by renal nuclear-imedicine procedures rather than by prescription volume. A typical commercial chain includes:

1. A reactor or isotope supplier produces molybdenum-99.
2. A generator converts molybdenum-99 into technetium-99m.
3. A radiopharmacy prepares the mertiatide kit with Tc-99m.
4. A hospital or imaging center administers the dose.
5. The provider bills for the imaging procedure and radiopharmaceutical component.

This structure limits the usefulness of conventional pharmaceutical market metrics. Kit sales represent only one portion of procedure revenue, and the economic value is distributed across the radiopharmacy, imaging provider, hospital, and isotope supply chain.

Market demand drivers

Demand is supported by:

• Chronic kidney disease and declining renal function in older adults
• Congenital urinary tract abnormalities in children
• Hydronephrosis and suspected ureteropelvic junction obstruction
• Renal transplant monitoring
• Continued use of functional imaging when ultrasound or CT does not resolve drainage questions
• Expansion of outpatient imaging and hospital radiopharmacy services

The market is mature. Growth is more likely to track imaging volumes, population aging, and installed nuclear-medicine capacity than new clinical adoption.

Market constraints

The main constraints are:

• Competition from Tc-99m diethylenetriaminepentaacetic acid, or DTPA
• Use of other renal tracers in certain markets
• Ultrasound, CT urography, MR urography, and other anatomic imaging
• Nuclear-medicine labor shortages
• Limited radiopharmacy coverage in lower-density regions
• Short product dating and dose logistics
• Intermittent molybdenum-99 and Tc-99m supply disruptions
• Hospital formularies that select products primarily on price and supply reliability

Who manufactures Technetium Tc 99m mertiatide kit?

The leading U.S. commercial product is Technescan MAG3, associated with Curium US LLC. Curium’s radiopharmaceutical portfolio includes diagnostic kits and prepared radiopharmaceutical products. The product has historically been associated with Mallinckrodt’s nuclear-imedicine business before the business became part of Curium.

The competitive structure differs from a conventional tablet market. Competition occurs among:

• Kit manufacturers
• Centralized radiopharmacies
• Hospital-based pharmacies
• Regional distributors
• Alternative renal tracers
• Imaging modalities that compete for the same clinical decision

A supplier with reliable manufacturing, regulatory compliance, isotope access, and broad radiopharmacy distribution can maintain commercial relevance even without patent exclusivity.

What is the FDA regulatory status of Technetium Tc 99m mertiatide kit?

The product is an FDA-approved diagnostic radiopharmaceutical kit. The FDA-approved use is the preparation of technetium Tc 99m mertiatide injection for renal imaging. The product is administered intravenously after radiolabeling and quality-control testing.

The kit is subject to requirements involving:

• Sterile manufacturing
• Radiopharmaceutical preparation
• Radionuclide identity and purity
• Chemical purity
• Bacterial endotoxin controls
• Labeling and expiration dating
• Radiation safety
• Dose calibration
• Distribution through licensed nuclear-pharmacy channels

The FDA label identifies the product’s clinical use, preparation instructions, dosing, warnings, and storage conditions. Because the final radioactive product has a short usable life, manufacturing and distribution controls are commercially important as well as regulatory requirements (FDA, n.d.-a).

What is the Orange Book status of Technetium Tc 99m mertiatide?

Technetium Tc 99m mertiatide is an old, mature radiopharmaceutical product with no meaningful market exclusivity comparable to a recently approved small-molecule drug.

The Orange Book is relevant because it records approved drug products and certain patent and exclusivity information. For a mature radiopharmaceutical kit, the principal commercial conclusions are:

• Product approval is longstanding.
• Any original composition or formulation exclusivity has expired.
• A current patent barrier is not the principal protection mechanism.
• Commercial protection depends on manufacturing capability, regulatory history, isotope access, distribution, and customer relationships.
• A new entrant would likely face product-development and supply-chain execution barriers rather than a dominant blocking patent.

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, should be reviewed for current sponsor, application, and patent-listing information because listings can change. Public market evidence does not indicate an active, high-value patent estate that materially delays competition in Tc-99m mertiatide kits (FDA, n.d.-b).

What patents protect Technetium Tc 99m mertiatide kit?

The commercial patent position is weak compared with branded pharmaceuticals launched under modern patent portfolios.

Potential historical patent categories include:

• Mertiatide composition patents
• Chelating-agent and radiolabeling technology
• Kit formulation patents
• Stabilizer and excipient combinations
• Radiopharmaceutical preparation methods
• Manufacturing and quality-control processes

For a mature Tc-99m mertiatide kit, those rights are generally expired or commercially limited. Method-of-use patents are also unlikely to create meaningful exclusivity because renal scintigraphy use has been established for decades.

Manufacturing know-how can still matter. A supplier may protect:

• Kit filling and lyophilization processes
• Shelf-life optimization
• Radiolabeling performance
• Quality-control procedures
• Distribution and dose-preparation systems

These protections are operational barriers, not substitutes for enforceable product exclusivity.

When does Technetium Tc 99m mertiatide lose exclusivity?

The product has already lost practical market exclusivity. Its commercial life extends beyond patent expiry because nuclear-medicine products often remain in use when they have:

• Established physician familiarity
• Validated imaging performance
• Existing reimbursement pathways
• Hospital protocols
• Regulatory approval
• Reliable radiopharmacy distribution

For this reason, generic entry does not necessarily produce the abrupt revenue collapse seen with a blockbuster oral drug. The market is already organized around multiple supply channels and price-sensitive institutional purchasing.

How strong is the patent estate for Technetium Tc 99m mertiatide?

The patent estate is weak as a current commercial defense.

Factor	Assessment
Original active-ingredient protection	Expired or commercially exhausted
Formulation protection	Limited practical value
Method-of-use protection	Unlikely to block routine renal imaging
Manufacturing know-how	Moderate operational value
Regulatory exclusivity	Expired for the mature product
Distribution capability	High commercial importance
Isotope access	High commercial importance
Litigation leverage	Low based on public market structure

The strongest barriers are manufacturing reliability and supply continuity. A new entrant would need to meet radiopharmaceutical manufacturing standards, establish validated kit performance, secure isotope inputs, and build a time-sensitive distribution network.

What generic entry risks exist?

Generic or competing-kit entry risk is structurally high because there is no durable patent moat. The practical risk is moderated by the small and specialized market.

A new competitor would face:

• Limited revenue per product
• High quality and regulatory requirements
• Short dating and inventory risk
• Need for rapid distribution
• Dependence on Tc-99m availability
• Institutional contracting pressure
• Established supplier relationships
• Physician and radiopharmacy switching costs

The most likely entry model is a regional or specialty radiopharmacy product rather than a large conventional generic launch. Price competition would be strongest in hospitals and centralized purchasing systems. Supply shortages could temporarily improve incumbent pricing, but those gains would be difficult to sustain.

What formulation patents protect Tc-99m mertiatide?

Formulation protection is unlikely to create substantial current exclusivity. A kit must maintain the chemical and radiolabeling properties needed to produce a consistent Tc-99m preparation. Relevant technical parameters include:

• Ligand concentration
• Buffer composition
• Reducing-agent performance
• pH control
• Lyophilization stability
• Radiochemical purity
• Reconstitution time
• Storage conditions
• Product dating

These requirements create regulatory and manufacturing hurdles. They do not necessarily create enforceable market exclusivity. A competing sponsor can seek approval for a comparable kit if it demonstrates acceptable quality, safety, and performance.

What patent litigation affects Technetium Tc 99m mertiatide?

There is no widely reported current Paragraph IV litigation or major patent dispute shaping the U.S. Tc-99m mertiatide market.

Paragraph IV litigation is less commercially central here than in high-value oral drugs because:

• The original product is mature.
• The market is relatively small.
• Patent barriers are limited.
• Commercial competition is based heavily on supply and distribution.
• Product revenue is not generally disclosed as a standalone blockbuster category.

The absence of major patent litigation does not eliminate regulatory risk. FDA manufacturing observations, product recalls, sterility failures, isotope shortages, or radiochemical-quality problems could affect supply more directly than patent enforcement.

What is the financial trajectory for Technetium Tc 99m mertiatide?

The expected financial trajectory is stable to modestly declining in real terms, with episodic supply-driven volatility.

Period	Expected commercial pattern
Near term	Stable clinical demand with price pressure and supply variability
Medium term	Low-single-digit volume changes tied to renal imaging activity
Long term	Gradual substitution risk from non-nuclear imaging and newer workflows
During isotope shortages	Temporary price and availability disruption
During new supplier entry	Greater contracting pressure and lower unit economics

Revenue growth is unlikely to come from premium pricing. It is more likely to come from increased imaging volumes, expanded radiopharmacy coverage, or improved manufacturing utilization.

The product’s economics are also sensitive to fixed costs. Sterile manufacturing, quality systems, radioactive-material handling, and distribution infrastructure can make a small-volume product unattractive even when gross margins appear favorable. A supplier with an existing radiopharmaceutical platform can achieve better economics than a standalone entrant because it can spread infrastructure across multiple products.

How does Tc-99m mertiatide compare with alternative renal imaging agents?

Product or modality	Main advantage	Main limitation
Tc-99m mertiatide	Strong renal extraction and functional drainage assessment	Requires radiopharmacy and Tc-99m supply
Tc-99m DTPA	Established renal perfusion and filtration imaging	Lower extraction than MAG3 in some patients
Ultrasound	No ionizing radiation and broad availability	Limited functional drainage quantification
CT urography	High anatomic detail	Radiation and contrast considerations
MR urography	Anatomic and selected functional information	Cost, access, and workflow complexity
Diuretic renography with MAG3	Effective for obstruction assessment	Dependent on protocol quality and patient preparation

Tc-99m mertiatide remains commercially relevant because it answers a functional question that is not always resolved by anatomic imaging. Its strongest position is in renography, obstruction assessment, and cases requiring quantitative differential renal function.

What licensing deals affect the product?

No major recently disclosed licensing transaction appears to be central to the current Tc-99m mertiatide market. Commercial rights are generally linked to product ownership, manufacturing transfers, distribution arrangements, and broader radiopharmaceutical portfolio transactions rather than a high-value molecule license.

The relevant transaction risks are operational:

• Transfer of manufacturing sites
• Change in product sponsor
• Distribution-partner changes
• Radiopharmacy network consolidation
• Acquisition of isotope or nuclear-medicine businesses
• Contracting changes with hospitals and group purchasing organizations

These events can affect availability and margin without changing the underlying clinical market.

What generic launch scenarios are most likely?

Three launch scenarios are commercially plausible:

1. Regional competitor: A radiopharmacy or specialty manufacturer launches in selected markets and competes on supply reliability.
2. Broad institutional entrant: A larger radiopharmaceutical company obtains approval and uses existing distribution contracts to compete nationally.
3. Shortage-driven entry: A new supplier enters after recurring supply disruptions create demand for an additional source.

The third scenario is the most commercially credible. Supply reliability can matter more than nominal unit price in radiopharmaceutical purchasing because missed doses can disrupt scheduled imaging and reduce hospital utilization.

Key Takeaways

• Tc-99m mertiatide kit is a mature renal-imaging radiopharmaceutical with established clinical demand.
• The product has no meaningful remaining market exclusivity based on public commercial evidence.
• Patent risk is low; manufacturing, isotope access, regulatory compliance, and distribution are more important barriers.
• Standalone product revenue is not publicly disclosed in a reliable, standardized form.
• The financial trajectory is stable to modestly declining, with temporary upside during supply shortages.
• Generic and competing-kit risk is high in principle but moderated by the small market and demanding radiopharmaceutical infrastructure.
• MAG3 remains differentiated for functional renal imaging, especially obstruction assessment and differential renal function.
• The strongest commercial asset is reliable supply, not patent protection.

FAQs

Is Tc-99m mertiatide the same as MAG3?

Yes. Tc-99m mertiatide is commonly referred to as Tc-99m MAG3, although MAG3 is also used as a product and clinical shorthand.

Is Technescan MAG3 a branded or generic product?

Technescan MAG3 is a branded commercial product, but it operates in a mature market with limited practical exclusivity and generic-style purchasing dynamics.

Can a hospital substitute Tc-99m DTPA for Tc-99m mertiatide?

In some clinical applications, yes. The choice depends on the diagnostic question, renal function, local protocol, physician preference, and product availability. The agents are not fully interchangeable for every renography indication.

Does Tc-99m mertiatide require a technetium generator?

The kit requires sodium pertechnetate Tc-99m for radiolabeling. The Tc-99m may come from a generator or another authorized supply source, depending on the radiopharmacy’s operating model.

What is the largest commercial risk for Tc-99m mertiatide?

The largest risk is supply-chain disruption involving Tc-99m availability, manufacturing, radiochemical quality, or time-sensitive distribution. Patent expiry is not the primary commercial risk for this mature product.

References

1. U.S. Food and Drug Administration. (n.d.-a). Technetium Tc 99m mertiatide kit: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA.

3. Curium Pharma. (n.d.). Technescan MAG3. Curium US LLC.

4. International Atomic Energy Agency. (2015). Technetium-99m radiopharmaceuticals: Manufacture and quality control. IAEA.

5. Society of Nuclear Medicine and Molecular Imaging. (2018). SNMMI procedure standard for diuretic renal scintigraphy in adults. Journal of Nuclear Medicine Technology.